Andreas Schmocker, CEO of Odne, is proud to announce the appointment of Steve Fanning as an independent board member.
“Steve joins us with tremendous leadership experience in dentistry and endodontics, bringing innovation to the market,” said Schmocker. “We are currently in the process of launching the Odne system in the United States, and Steve’s background in building businesses in endodontics will be a tremendous asset as we look to expand Odne’s presence.”
Stephen C. Fanning, Board Member, Odne
“I am honored and excited to work with the talented team at Odne to bring innovation to dentistry/endodontics,” said Fanning. “It is an exciting time to join the Odne team as we strive to transform endodontics. The Odne system has the potential to empower clinicians to perform endodontic procedures with greater confidence and enable them to provide patients with better outcomes. I couldn’t be more proud of the team and the work they are doing.”
Odne recently launched a Priority Access Program (PAP) for its innovative Root Preservation Therapy (RPT) at the AAE Annual Meeting in Los Angeles. PAP will form the core of Odne’s scientific and clinical community, transforming endodontics. A PAP initiative is to conduct a clinical case registry, gathering further knowledge about the clinical use of Odne’s devices for root canal treatment. Participating Endodontists have the opportunity to be among the early adopters of Odne devices and provide valuable and scientific feedback on use.
Odne Fill is the first FDA-cleared light-curing, injectable endodontic filling material. Odne Fill is a hydrogel, a class of biomaterials known for their excellent biocompatibility and hydrophilicity. Due to its water-like viscosity and extremely high hydrophilicity in its uncured state, it can flow into complex endodontic structures such as isthmuses, deltas and C-shaped canals. After curing with Odne Cure, the corresponding microlaser polymerization device, provides gap-free root canal sealing and long-term occlusion.
OdneClean aims to establish an unorganized approach to RPT. A cleaning tip as thin as 190 µm creates a hydrodynamic cavitation cloud using normal saline inside the root canal. The cavitation jet removes debris inside channels and pipes. FDA clearance for OdneClean is expected in the 2nd half of 2024.
About Steve Fanning
Steve has over 25 years of commercial and general management experience in the healthcare industry, delivering consistent results that drive growth with mature businesses and building growth playbooks for newer businesses. Earlier in his career, Steve worked at Johnson & Johnson in the Tylenol, Splenda and Neutrogena brand businesses. In 2010, he joined Danaher (now Envista) and was promoted to vice president/general manager of infection prevention and specialties for Danaher’s Dental Division in 2014. Steve moved to Henry Schein in 2018 as vice president/general manager of restorative and business endodontic unit, offering high growth results. Most recently, Steve worked as the CEO of a healthcare startup.
Steve holds a BBA from the University of Michigan with a concentration in marketing and finance, and an MBA from the Wharton School at the University of Pennsylvania with a concentration in strategy and marketing.
About Odne
Odne AG (formerly Lumendo AG) has its roots in a pioneering collaboration between two renowned Swiss institutions: the Swiss Federal Institutes of Technology in Lausanne and Zurich (EPFL & ETH Zürich). Founded in 2018, Odne’s journey began by licensing cutting-edge technology assets from these esteemed institutes.
Odne is committed to pioneering the future of endodontics through advanced technology and innovative solutions. Endodontics, the branch of dentistry that deals with root canal treatments, has been marred by complexity and unpredictability. Odne is on a mission to change that.
Root canal treatments have long posed challenges for dentists, with traditionally low success rates ranging from 46% to 91%. With more than 60 million annual treatments worldwide, these failures result in significant healthcare costs. Odne’s technology platform seeks to address these issues by offering treatment options for both dentists and their patients. Launched in the US in April 2024, Odne’s medical device portfolio addresses issues such as occlusion of complex root canal morphologies.
Recently, Odne Inc, USA, was established to create the organization to support the launch in the USA.
Odne is backed by venture capital funds focused on healthcare and dentistry. These include Revere Partner (NY), an independent venture fund providing capital for cutting-edge innovations in oral and systemic health, and NV Capital (LIE), a family-owned venture capital boutique that led the Series A1 funding. In addition to the main investors, other well-known funds such as the Dental Innovation Alliance (DIA), Plug&Play, Hatcher, Züricher Kantonalbank, as well as various family offices and angel investors are supporting the launch of Odne in the US market.
Odne’s technology platform for root preservation therapy (RPT), including: the first hydrodynamic cavitation device that uses saline as the primary cleaning agent and the first all-in-one, light-cured filling material.
Disclaimer: Odne Fill and Odne Cure are cleared for use in the US only. All other Odne devices are currently in development and have not been licensed for clinical use.
For more information, visit www.odne.co.
